The Complete Cellular Energy Peptide Protocol

Your mitochondria are not just power plants. They are dynamic, membrane-dependent machines that require specific raw materials, intact structural components, clean operating conditions, and the right signaling environment to function at anything close to their ceiling. Most people are missing at least two of those four things, and the protocol in the video is designed around that reality, where each tier addresses a different part of the same system.

The place to start is with the system itself.

Every cell in your body produces energy through a process that happens across the inner membrane of your mitochondria. That membrane contains a chain of protein complexes, and electrons pass through those complexes in sequence, releasing energy that gets used to pump protons across the membrane, and that proton gradient is what drives the production of ATP, which is what your cells actually use as fuel. The whole chain depends on the membrane staying tightly organized and structurally intact, and the chain depends on having enough of something called NAD+, which is a molecule that carries electrons into that chain in the first place. No NAD+, no electrons moving. No membrane integrity, no proton gradient. No proton gradient, no ATP.

That is the whole map. Every tier in this protocol connects back to one of those steps.

Tier one, the foundation supplements, is not glamorous, but it is the rate-limiting step for everything else. Creatine at five grams per day replenishes phosphocreatine, which buffers ATP between production cycles so your cells do not run out between heartbeats or muscle contractions. CoQ10 sits directly inside the electron transport chain as a carrier molecule between complexes one and three, and without it the chain backs up. Magnesium is a cofactor for over 300 enzymatic reactions, including several that are directly involved in ATP synthesis. Zinc, D3, and fish oil all reduce the baseline inflammatory load that consumes mitochondrial resources. If the foundation is incomplete, optimizing anything upstream is like trying to run a factory with the power cut to half the machines.

Tier two is NAD+ support, and this is where the age dependency starts to matter in a measurable way.

NAD+ declines with age, and that decline is well documented across tissues. The reason you can cycle injectable NAD+ eight to twelve weeks on with four to eight weeks off is because long-term supplementation can suppress something called NAMPT, which is the enzyme that synthesizes NAD+ endogenously. Your body reads the extra supply and dials down its own production, so you cycle to preserve that enzyme's baseline activity. Younger people in the 35 to 45 range may get adequate results from oral precursors like NMN because their NAMPT activity is still high enough to convert precursors efficiently, but past a certain age that enzymatic machinery slows down and injectable bypasses the conversion step entirely.

Tier three is where the biology gets more specific, and this is the cleanup phase.

As cells accumulate damage they can enter a state called senescence, where they stop dividing but do not die, and they start secreting inflammatory signals that damage neighboring tissue. The compound FOXO4-DRI works by disrupting a survival signal inside senescent cells specifically, because those cells overexpress a protein called FOXO4 that keeps them alive by binding to p53, which is the protein that would otherwise trigger cell death. FOXO4-DRI is a peptide that blocks that binding, and in the 2017 research by de Keizer et al., it showed an 11.73-fold selectivity for senescent cells over healthy ones, meaning it is not randomly killing tissue. The caveat the video names is real: this is still preclinical, the human data is limited, and the mechanism is well described but the long-term safety picture in humans is not complete.

Epithalon works differently, through something called telomerase activation, which is the enzyme that maintains the protective caps on chromosomes. The research base here is a mix of animal data and limited human studies, and the evidence is promising but not definitive. Both compounds are run once or twice a year for short cycles because the goal is periodic clearance, not constant intervention.

Tier four is the core energy stack, and this is where the mechanism becomes worth understanding in detail.

SS-31, also called elamipretide, targets something called cardiolipin, which is a phospholipid that sits in the inner mitochondrial membrane and physically organizes the protein complexes of the electron transport chain into clusters called supercomplexes. When cardiolipin is oxidized and damaged by reactive oxygen species, those supercomplexes fall apart, the chain becomes inefficient, and electron leakage increases, which produces more reactive oxygen species and creates a self-reinforcing cycle of membrane damage. SS-31 binds directly to cardiolipin, stabilizes it, reduces that electron leakage by somewhere between 40 and 60 percent based on the Szeto 2014 data, and allows the supercomplexes to reform. In the TAZ-POWER trial published in 2024, patients treated with SS-31 over three years gained 96 meters on a six-minute walk test and showed 45 percent improvements in leg strength and cardiac function. That is a structural repair mechanism producing measurable functional output.

MOTS-c addresses the other side of the equation. It is a peptide that originates from the mitochondrial genome itself, which is unusual, and it activates something called AMPK, which is a cellular energy sensor that improves how efficiently cells use glucose and fatty acids, increases insulin sensitivity, and reduces the oxidative stress that was damaging the membrane in the first place. The 2026 Gudiksen data showed that MOTS-c improves intrinsic mitochondrial efficiency, not just systemic signaling. SS-31 repairs the hardware. MOTS-c improves the operating system. Those are genuinely non-overlapping mechanisms, which is why stacking them makes pharmacological sense.

Tier five is conditional because it only corrects dysfunction that is actually present.

5-Amino-1MQ blocks an enzyme called NNMT, which in people with excess adipose tissue is diverting NAD+ precursors away from the energy system and into pathways that promote fat cell expansion. In the mouse study by Nkandeu et al., NNMT inhibition produced a 35 percent reduction in body mass. That is a large effect, but it is also a mouse study and the human data is not there yet. If you are lean and metabolically healthy, there is no NNMT overactivity to block and the compound does nothing meaningful. Methylene blue can donate electrons directly into the chain, but it interacts with the serotonin system at higher doses, which is why SSRI use is a hard contraindication, and G6PD deficiency prevents it from being safely metabolized. Injectable L-carnitine solves an actual absorption problem because oral carnitine has poor bioavailability, and the mitochondria need carnitine to physically move long-chain fatty acids across the inner membrane for oxidation.

The thing most people miss about this protocol is that each tier assumes the previous one is working.

You cannot meaningfully repair cardiolipin if the cell is operating in a high-oxidative-stress environment driven by inadequate magnesium and CoQ10. You cannot improve NAD+ driven electron flow if the membrane is too damaged to use it efficiently. You cannot optimize energy production in a tissue environment where senescent cells are constantly releasing inflammatory signals that impair mitochondrial biogenesis. The tiers are not independent options you can cherry-pick. They are a sequential argument about what the system needs and in what order.

That is not a protocol. That is a model of how cellular energy actually fails.

---

References

1. Thompson WR et al. TAZ-POWER trial. Genetics in Medicine. 2024;26(7):101133 — SS-31 (elamipretide) +96m on 6MWT, +45% leg strength/cardiac function over 3 years
2. Szeto HH. Mitochondria-targeted cytoprotective peptides. British Journal of Pharmacology. 2014;171:2029-2050 — SS-31 mechanism, cardiolipin binding, 40-60% ROS reduction
3. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015 — MOTS-c AMPK activation, insulin sensitivity
4. Gudiksen A et al. Free Radical Biology and Medicine. 2026;246:682-696 — MOTS-c improves intrinsic mitochondrial efficiency
5. de Keizer et al. Targeted apoptosis of senescent cells. Cell. 2017 — FOXO4-DRI senolytic mechanism, 11.73-fold selectivity
6. Khavinson et al. Epithalon telomerase activation research — limited human + animal data
7. Nkandeu et al. 5-Amino-1MQ mouse study — 35% body mass reduction, NNMT inhibition in adipose tissue

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness